Polychem (506605)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Reported P/E of 4.80 gives an optically low valuation, though earnings quality needs scrutiny.
• Piotroski F-Score of 6/9 indicates broadly reasonable financial health without immediate distress signals.
• Book value per share of ₹913.92 provides a tangible asset base, even though the price trades at 3x book.
• ROE of 11.31% and ROCE of 10.03% show positive, if unexciting, returns on capital.

Concerns

• Latest quarter sales of just ₹9 Cr against net profit of ₹25 Cr strongly suggests non-operating or exceptional income, not core business earnings.
• Sales growth of -15.38% shows a shrinking topline, while profit growth of 1,000% is a low-base distortion rather than sustainable momentum.
• At P/B of 3.01, investors are paying a steep premium to book value for a commodity chemical company with mediocre ROE.
• Dividend yield of 0.89% offers negligible income, and promoter holding data is unavailable, leaving governance transparency unclear.

AI Analysis

At face value, a P/E of 4.8 and profit growth of 1,000% look tempting. But Mr. Market is not always stupid. Polychem is a commodity chemical producer whose latest quarter tells a worrying story: sales of just ₹9 crore, yet net profit of ₹25 crore. Profit exceeding revenue is a red flag, not a badge of quality; it almost certainly reflects non-operating or exceptional income. A single such quarter cannot justify Graham's 'margin of safety'. With sales down 15.38%, the core business is shrinking, and 1,000% profit growth is a low-base trick. ROE of 11.31% and ROCE of 10.03% are mediocre for a commodity business. The Piotroski score of 6/9 is passable, but not a moat. Book value of ₹913.92 means I'd pay 3.01 times assets for a company with falling sales and uncertain earnings. That lacks margin of safety. Dividend yield 0.89% gives little comfort to minority shareholders. The market cap of ₹111 crore makes it a small-cap; small can be nimble, but it can also be fragile. The 52-week range shows the price has already run from ₹1,811 to ₹2,750, so much optimism is baked in. I would need evidence that the ₹25 crore quarterly profit is recurring, that core sales have stopped declining, and that the company can earn a return on capital well above its cost of capital. Without that, this is a cyclical, commodity-chemical puzzle — optically cheap, probably intrinsically ordinary. In Buffett's game, it is far better to buy a wonderful business at a fair price than a mediocre business at a seemingly low multiple. I will pass.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer